SoCalBio

  • Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
    on May 24, 2024

    IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., announced today that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 31st – June 4th, 2024, in Chicago, Illinois. The presented data underscores Agendia’s commitment to advancing individualized management of breast cancer and to providing support throughout a patient’s treatment journey. These studies add to the already robust library of

  • Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
    on May 24, 2024

    EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois. Details of the presentation are as follows: Abstract

  • Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
    on May 23, 2024

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.

  • City of Hope Researchers to Present Investigational Treatments for Colorectal, Kidney and Blood Cancers at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    on May 23, 2024

    LOS ANGELES--(BUSINESS WIRE)--World-renowned physicians and researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present new data and offer expert perspectives on leading-edge cancer research and treatments in development at the 2024 ASCO Annual Meeting, which will take place in Chicago from May 31 to June 4. Highlights include the following: 2024 Best of ASCO® program: New data on mismatched unrelated donor peripheral blood s

  • StrokeDx Raises Oversubscribed $5 Million Seed Prime Round to Advance Next-Generation Stroke Technology
    on May 23, 2024

    PASADENA, Calif.--(BUSINESS WIRE)--StrokeDx, a pioneer in next-generation stroke technology, today announced the successful closing of $5 million in Series Seed Prime funding. The oversubscribed round was led by DigiTx Partners, with participation by Freeflow Ventures and other existing investors with extensive accomplishments across neuroradiology, stroke, and medical devices. David J. Kim, MD, Managing Director of DigiTx Partners, will be joining the board. To date, StrokeDx’s technology has

  • ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
    on May 23, 2024

    LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event. To arrang

  • Turn Therapeutics invites public investment for expansion of flagship wound formula into eczema, toenail fungus
    on May 23, 2024

    LOS ANGELES--(BUSINESS WIRE)-- #Eczema--Turn Therapeutics launched its first public investment campaign today to expand its flagship wound formula into eczema, toenail fungus.

  • New Biomarkers Found to Predict Kidney Failure in Type 1 Diabetes Patients
    on May 22, 2024

    LOS ANGELES--(BUSINESS WIRE)--In a paper published today in Science Translational Medicine, researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, report that they have discovered advances in predicting kidney failure in type 1 diabetes (T1D) patients. By performing the first epigenome-wide association analysis in patients with diabetic kidney disease, a

  • Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
    on May 22, 2024

    IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a clinical-stage biotech developing innovative secretome therapies to address age-related disease and immune dysfunction, obtained a significant strategic milestone in partnering with Toray, a Japanese drug company part of the Toray Group. Founded in 1926, Toray has grown into a highly successful conglomerate known for its commitment to solving pressing global health and environmental challenges. With its production of various advanced material sc

  • ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
    on May 22, 2024

    LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce that its flagship ingredient, Niagen® (patented nicotinamide riboside, NR), the most efficient and high-quality NAD+ booster and the active ingredient in the company’s consumer supplement, Tru Niagen®, has been awarded the NutraIngredients EU Healthy Ageing Ingredient of the Year Award. This recognition underscores the sig

  • AppliedVR launches RelieVRx® for workers’ compensation patients, payers and physicians
    on May 22, 2024

    LOS ANGELES--(BUSINESS WIRE)-- #VR--AppliedVR launches its flagship RelieVRx device that uses immersive virtual reality to help workers' comp patients reduce chronic lower back pain.

  • Court Revokes Two Advanced Cell Diagnostics Patents, Dismisses Infringement Claims Against Molecular Instruments and Orders Advanced Cell Diagnostics to Make Payment of £1.35 Million to Molecular Instruments
    on May 21, 2024

    LOS ANGELES--(BUSINESS WIRE)-- #Biotech--Molecular Instruments announced that UK Patents Court orders Advanced Cell Diagnostics to make £1.35 million costs payment to Molecular Instruments.

  • Enshrining Inequity is Immoral: Vote No on the Pandemic Agreement, says AHF
    on May 21, 2024

    LOS ANGELES--(BUSINESS WIRE)--As the final stage of negotiations of the World Health Organization (WHO) Pandemic Agreement nears conclusion, the AIDS Healthcare Foundation voices major concerns about the latest Proposal for the Agreement. Much has changed since March 30, 2021, when during the COVID-19 pandemic, leaders from Europe and other developed countries held hands while touting commitments for an agreement guided by “solidarity, fairness, transparency, inclusivity, and equity.” The mood

  • Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
    on May 21, 2024

    LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Publishes ADORING 1 & 2 Pivotal Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children with Atopic Dermatitis in JAAD

  • City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
    on May 20, 2024

    LOS ANGELES--(BUSINESS WIRE)--City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its Duarte, California, campus that will further expand its scientific capabilities. The mission of the unique Stem Cell-Based Disease Modeling Laboratory is two-fold. First, it will advance stem cell-based disease modeling

  • Sonendo to Present at the 2024 Stifel Jaws & Paws Conference
    on May 20, 2024

    LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (OTCQX: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will present at the upcoming 2024 Stifel Jaws & Paws Conference. Management is scheduled to present on Wednesday, May 29th at 12:00 p.m. Pacific Time/ 3:00 p.m. Eastern Time. An audio webcast of the presentation will be available on the “Investors” section of the company’s website at: investor.sonendo.com. About Sone

  • California’s Life Science Industry Generates $414.2 Billion Annually
    on May 20, 2024

    SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today released a new report showing California’s life science industry directly provides more than 465,000 jobs in the state and generates $414.2 billion in total business output. Biocom California’s 2024 Economic Impact Report outlines these and other key findings about the state’s life science industry, including information on economic,

  • Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
    on May 20, 2024

    THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric patie

  • FIGS to Outfit 250+ Team USA Healthcare Professionals at the 2024 Olympic and Paralympic Games
    on May 20, 2024

    SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS (NYSE: FIGS), the renowned medical apparel brand, announced today a multi-year agreement with The U.S. Olympic & Paralympic Committee (USOPC) and The LA28 Olympic and Paralympic Games (LA28), highlighting the Awesome Humans who push the limits every day to support their patients in life’s most critical moments. Beginning with this year’s Olympic and Paralympic Games in Paris, FIGS will outfit the 250+ healthcare professionals supporting Team USA O

  • Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
    on May 20, 2024

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville. “Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our P

  • Masimo Receives Sustainability Seal of Approval from Practice Greenhealth
    on May 20, 2024

    IRVINE, Calif. & RESTON, Va.--(BUSINESS WIRE)--Masimo is the first pulse oximetry manufacturer recognized by Practice Greenhealth as Greenhealth Approved, for Masimo RD pulse oximetry sensors.

  • mBIOTA Labs Announces Results from First Prospective Clinical Trial of Novel, Palatable Elemental Diet in Patients with SIBO and IMO
    on May 20, 2024

    SANTA MONICA, Calif.--(BUSINESS WIRE)--mBIOTA Labs, a medical food company revolutionizing oral nutrition through their proprietary palatable elemental diet, mBIOTA Elemental™, today announced the initial study results of their first prospective clinical trial assessing the efficacy of the mBIOTA Elemental™ diet in patients with small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), or a combination of the two. Presented in an abstract at Digestive Disease Week 20

  • Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
    on May 20, 2024

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar la

  • Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
    on May 17, 2024

    CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research. Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific at ImmunityBio, discussed the breakin

  • Adagio Medical Announces First European Commercial Procedures and Commencement of U.S. FDA Pivotal IDE for Ventricular Tachycardia Cryoablation System
    on May 16, 2024

    LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration (“FDA”) approval of the FULCRUM-VT Pivotal IDE study of the VT Cryoablation System. VT procedures remain highly

  • Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
    on May 16, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said Dr. Ailsa Wilson Edwards, a urologist at Calvary North Adelaide Hospital. “I

  • A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
    on May 16, 2024

    AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2Bio--A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T

  • Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
    on May 15, 2024

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its participation in the Women’s Wear Daily (WWD) Beauty CEO Summit. This summit brings together the leading retailers, marketers, and creative minds across all categories to help prepare for the next phase of global beauty while driving growth and innovation today. At the global consumer beauty event, President and

  • Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
    on May 15, 2024

    LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of the completely redesigned GastroPlusX (GPX), the next generation PBPK/PBBM modeling & simulation software.

  • Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
    on May 14, 2024

    TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt’s cutting-edge clinical capab

  • NIH-Funded Study Shows BDI's Bone Density Test Using Existing CT Images Predicts Fractures
    on May 14, 2024

    TORRANCE, Calif.--(BUSINESS WIRE)-- #BDI--NIH study: BDI's CT bone test predicts fractures, aids early osteoporosis detection, cost-effectively. Visit www.bdi.ai.

  • Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
    on May 14, 2024

    SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain. Four presentations will highlight real-world experience with Yescarta (axicabtagene ciloleucel), including manufacturing experience for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) i

  • Radiometer and Etiometry announce commercial partnership to empower physicians by optimizing workflows and decision making in high acuity care settings
    on May 14, 2024

    BOSTON & BREA, Calif.--(BUSINESS WIRE)--Radiometer, a leading medical device company specializing in acute care testing solutions, and Etiometry, a leader in clinical decision-support software for critical care, today announced a new commercial partnership to enhance clinical decision making and workflows in hospital settings. Integrating the Etiometry platform with Radiometer’s acute care diagnostic solutions, empowers clinicians in critical care settings to view blood gas results, along with

  • Donaldson and PolyPeptide Partner to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology
    on May 13, 2024

    MINNEAPOLIS & TORRANCE, Calif.--(BUSINESS WIRE)-- #Acetonitrile--Donaldson Company, Inc. (NYSE: DCI), a leading worldwide manufacturer of innovative filtration and separation products and solutions, and PolyPeptide Group AG (SIX: PPGN), a global leader in peptide manufacturing, today announced their collaboration on the development of a production scale solvent recovery system for use in peptide purification. Peptides are used as the active pharmaceutical ingredient (API) in therapeutic areas, which continue t

  • One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)
    on May 13, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery ( JVS1). The study demonstrated that the DETOUR System offers a viable endovascular option for patients with long segment, complex superficial femoral artery (SFA) disease. Percutaneous Tr

  • Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    on May 10, 2024

    NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units (RSUs) of the company’s common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of

  • MDI Health Wins Best New Technology Solution for Medication Management Award
    on May 10, 2024

    LOS ANGELES--(BUSINESS WIRE)--MDI Health Wins Best New Technology Solution for Medication Management Award, 8th Annual MedTech Breakthrough Awards.

  • Xencor Reports First Quarter 2024 Financial Results
    on May 9, 2024

    PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights. “We have focused our XmAb® clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers, which continue to show clinical validation for t

  • Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    on May 9, 2024

    REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,

  • FIGS Releases First Quarter 2024 Financial Results
    on May 9, 2024

    SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the “Company”), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its first quarter 2024 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results. “Net revenues came in at the upper end of our expectations with adjusted EBITDA margin(1) exceeding our guidance. Importantl

  • Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
    on May 9, 2024

    REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,

  • Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
    on May 9, 2024

    PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results. Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has achieved significant progress across our broad pipeline of investigational RNAi-based medicines that leverage the proprietary TRiMTM platform a

  • Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
    on May 9, 2024

    THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024. "Our lead CAR T program, ATA3219, is advancing as a promising new therapeutic option for oncolo

  • Tool To Warn Of Concussions Wins Grand Prize At Sunstone CSU Startup Launch Competition 2024
    on May 9, 2024

    CARSON, Calif.--(BUSINESS WIRE)--2024 Sunstone CSU Startup Launch winner announced at CSU Dominguez Hills.

  • Reflow Medical Completes Enrollment in the DEEPER REVEAL Clinical Trial
    on May 9, 2024

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces completion of enrollment in the DEEPER REVEAL clinical trial (NCT05358353) to evaluate the Reflow Spur™ Stent. Designated a Breakthrough Device by the FDA, the Spur is a unique clinical solution intended to provide stent-like results while leaving no metal behind. The study enrolled 130 patients in over 35 clinical centers in the U.S. “The steady rate of en

  • Sonendo, Inc. Reports First Quarter 2024 Financial Results and Announces Strategic Reset Priorities
    on May 8, 2024

    LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (OTCQX: SONX) (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the first quarter ended March 31, 2024 Recent Highlights Recorded total revenue of $7.0 million for first quarter of 2024, exceeding previously issued guidance of $6.0 million; ending the quarter with installed base of 1,142 and achieved a healthy console backlog Increased average procedure instrument se

  • ChromaDex Corporation Reports First Quarter 2024 Financial Results
    on May 8, 2024

    LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.2 million, with $17.4 million from Tru Niagen®. Solid gross margin of 60.7%, an increase of 80 basis points, compared to 59.9% from the prior year quarter. Sales and marketing expense as a percentage of net sales was 30.4%, an improvement of 450 basis points, compared to 34.9% from the

  • CORRECTING and REPLACING SG Homecare Buys Western Drug Medical Supply, Fueling Growth In California and Beyond
    on May 8, 2024

    TUSTIN, Calif.--(BUSINESS WIRE)--Headline of release should read: SG Homecare Buys Western Drug Medical Supply, Fueling Growth In California and Beyond The updated release reads: SG HOMECARE BUYS WESTERN DRUG MEDICAL SUPPLY, FUELING GROWTH IN CALIFORNIA AND BEYOND SG Homecare, Inc., a leading provider of in-home medical equipment and supplies, announced today the acquisition of Western Drug Medical Supply. This strategic move unites two industry leaders, creating a platform to dramatically scal

  • Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable and Morpheus Moldable Products
    on May 8, 2024

    IRVINE, Calif.--(BUSINESS WIRE)-- #FDAclearance--Irvine-based Biogennix, LLC an osteobiologics company specializing in bone graft products for fusion procedures, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its Agilon Moldable and Morpheus Moldable bone grafting products. The new clearance allows the products to be used in the intervertebral disc space as an autograft extender, with an FDA-cleared intervertebral body fusion device

  • Masimo to Present in BofA Securities Health Care Conference
    on May 8, 2024

    IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities Health Care Conference on Wednesday, May 15, 2024 at 4:20 p.m. Pacific Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-lead